Luxbright (LXB.ST) Stock Analysis & AI Equity Report

Medical - Devices SEK Explore free reports

Luxbright (LXB.ST) overview

Luxbright (LXB.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Luxbright reported revenue of SEK 9.0m and operating profit of SEK -18.1m; the year-end share price was 0.86 SEK and market capitalisation was SEK 88.1m. Luxbright is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Luxbright's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 34.2mFY 2024
Share price0.86 SEKFY 2024 year end
RevenueSEK 9.0mFY 2024
Operating profitSEK -18.1mFY 2024
Net earningsSEK -17.7mFY 2024
Market capitalisationSEK 88.1mFY 2024 year end

Figures updated on 2025-09-29. Data will be refreshed during report generation.

About Luxbright

Luxbright AB develops and manufactures X-ray tubes and X-ray sources for industrial imaging applications. Its main offerings include microfocus X-ray tubes, microfocus X-ray sources for integration in imaging systems, and custom-made tubes for specific customer requirements. The company also develops cold cathode technology intended to improve X-ray performance and efficiency.

Generate the Luxbright report

Luxbright is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Luxbright and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.